Potentially true Overinterpreted Certainty of evidence: low provisional C-BAR-04

Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

In short: This claim is possibly true but overstated: Barrett's oesophagus is found in a few percent of patients after sleeve gastrectomy, but estimates vary widely, absolute risks are small, and the archive's own key trial (SLEEVEPASS) found the same 4% after gastric bypass.

Conclusion: Barrett's is documented after sleeve, but the archive's key trial shows no sleeve-specific excess.

Original statement
Scientific assessment
Scientific evidence in detail
In plain language
Studies on this claim
Regional context
What applies in my country?
References

Original statement

والتكميم تحديداً يترك المريء عرضةً: بعد عقد كامل في تجربة SLEEVEPASS العشوائية، كان التهاب المريء في 31% من مرضى التكميم مقابل 7% فقط للمجازة، ومريء بارت في 4%.

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

Origin

Source status: Archive editors
Attribution: Archive editors (eltayebat.com); not necessarily Elawady's own words
Origin: https://eltayebat.com/rule/bariatric-surgery/
Attribution uncertainty: Editorial summary/narrative and study selection written by the archive operators; the archive states that the cited research documents harm independently of Dr. Diaa's words.

Claimed mechanism: Chronic acid exposure causes metaplasia.
Claimed health effect: Barrett's oesophagus (pre-cancerous change).
Population concerned: Sleeve patients
Geographic restriction by Elawady: not applicable (archive text)

Scientific assessment

Potentially true – Some evidence points in favour of the statement, but it is not sufficient for a clear judgement.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

That sleeve causes Barrett's oesophagus, illustrated with SLEEVEPASS (4%).

2. What is demonstrably correct?

De novo Barrett's is found after sleeve: pooled 5.6% (I-BAR-04), 6.7% (I-BAR-110, possibly overestimated) and 8% (I-BAR-109); 15-18.8% in small series (A-BAR-08, A-BAR-09). Compared with liraglutide-treated patients, coded Barrett diagnoses were more frequent after sleeve (0.3% vs 0.1%, RR 2.70; I-BAR-115).

3. What is wrong or exaggerated?

SLEEVEPASS found Barrett's in 4% after sleeve AND 4% after bypass (P=.29); the authors said incidence was 'markedly lower than in previous trials and similar after both procedures'. The archive narrative and Arabic headline present the 4% as a sleeve-specific penalty.

4. What remains unclear?

Whether sleeve raises Barrett's compared with untreated obesity is not established: the liraglutide comparison is prone to detection bias, IFSO estimates 2.4% after all bariatric procedures with weak data (I-BAR-114), and two RCTs found similar Barrett rates after sleeve and bypass (A-BAR-07; Oseberg I-BAR-116). Oesophageal cancer after sleeve is rare (about 4 per 100,000 person-years; I-BAR-117) and its long-term risk unknown.

5. Which studies support it?

A-BAR-08, A-BAR-09, I-BAR-04, I-BAR-109, I-BAR-110, I-BAR-115.

6. Which studies contradict it?

A-BAR-07 (no difference vs bypass), I-BAR-116 (similar Barrett after sleeve and bypass), I-BAR-114 (2.4% pooled after MBS).

7. What applies to Germany and Europe?

Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.

8. What is known about Egypt?

No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.

9. What practical conclusion is appropriate?

Endoscopic surveillance after sleeve is advised by some authors; the absolute Barrett's risk appears to be in the single-digit percent range in larger data.

Assessment details

Rationale for certainty of evidence: Barrett's after sleeve is documented (pooled de novo 5.6%), but studies are mostly uncontrolled and heterogeneous, and the only RCT shows no difference vs bypass.
Source quality: Archive editorial; numbers from SLEEVEPASS quoted correctly but framed as sleeve-specific.
Regional transferability: European data.
Individual exceptions: Risk higher with persistent GERD symptoms (meta-regression).
Regional scope of the claim: general (biological/medical)
Last reviewed: 26 October 2026 provisional

Scientific evidence in detail

Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).

Research question: Does sleeve gastrectomy increase the risk of Barrett's oesophagus compared with no surgery or with gastric bypass, and is the archive's SLEEVEPASS figure (4%) correctly used?

Research question in detail (PICO)

Population

Adults after sleeve gastrectomy

Intervention or exposure

Sleeve gastrectomy

Comparison

Gastric bypass; non-surgical obesity treatment; preoperative status

Geographic scope

universal biology

Outcomes

Barrett's oesophagus (de novo)
Oesophageal adenocarcinoma

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

Meta-analysis: Barrett's after sleeve

Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041 Meta-analysisabstract checked

Meta-analysis of long-term studies: de novo Barrett's after sleeve.

Actual result
Pooled 5.6% (3.5-8.8).
Methodological quality
moderate
Relevance
direct
Limitations
Uncontrolled, heterogeneous

Original publication
Sleeve vs a weight-loss drug: Barrett changes

Butt et al.. Ann Gastroenterol 2026 · PMID 42164611 · DOI 10.20524/aog.2026.1058 Cohort studyabstract checkednewly added

Matched cohort: Barrett diagnosed more often after sleeve than with liraglutide.

Actual result
0.3% vs 0.1%; RR 2.70 (1.31-5.56).
Methodological quality
low (detection bias)
Relevance
direct (non-surgical comparator)
Limitations
More endoscopy after surgery

Original publication

What speaks against the claim?

Finnish trial: sleeve vs bypass after 10 years

Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229 Randomised controlled trialabstract checked

SLEEVEPASS RCT: Barrett's equally frequent after sleeve and bypass.

Actual result
4% vs 4% (P=.29).
Methodological quality
high (RCT)
Relevance
direct
Limitations
Small numbers

Original publication
Norwegian trial: bypass vs sleeve in type 2 diabetes

Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6 Randomised controlled trialabstract checkednewly added

Oseberg RCT: Barrett prevalence similar after sleeve and bypass at 5 years.

Actual result
Similar (numbers not in abstract).
Methodological quality
high but small
Relevance
direct
Limitations
n=109

Original publication
International society statement on endoscopy and Barrett

Brown et al.. Obes Surg 2025 · PMID 41108366 · DOI 10.1007/s11695-025-08206-8 Guideline / position statementabstract checkednewly added

IFSO 2025: pooled Barrett incidence after any MBS 2.4%, with weak data.

Actual result
2.4% (1.66-3.45).
Methodological quality
moderate
Relevance
indirect (all procedures)
Limitations
Short follow-up

Original publication

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Barrett's oesophagus occurs after sleeve in a few percent of patients; whether sleeve raises it above the risk of obesity itself is plausible but not proven, and randomised comparisons with bypass show no clear excess.

Why some studies weigh more

Randomised comparisons with endoscopy weigh most for the comparative question; meta-analyses of uncontrolled series likely overestimate (reporting bias acknowledged in I-BAR-110).

Is a causal relationship established? Possible, not established Biologically plausible via chronic reflux; controlled data inconsistent.

Remaining uncertainty

Excess over non-operated obese people; progression to cancer.

Justified conclusion

Possibly true that sleeve exposes the oesophagus to some Barrett risk; the archive overstates by presenting the SLEEVEPASS 4% as sleeve-specific.

Why do studies seem to disagree?

Estimates range from 0.3% (coded diagnoses) to about 19% (single-centre systematic endoscopy). Differences reflect detection method, selection and follow-up, not true contradictions. RCTs comparing sleeve with bypass (SLEEVEPASS, Oseberg) found similar Barrett rates; a small selected RCT follow-up (I-BAR-145) found 30.8% vs 13.6% (NS).

Does this depend on the country?

General biological effects: Universal.
Eating habits: Not applicable (surgical procedure, not a food).
Origin of the food: Not applicable (surgical procedure, not a food).
Contaminants: Not applicable (surgical procedure, not a food).
National production conditions: Endoscopic follow-up practices vary.
Legal rules: Not applicable.
Actual monitoring data: No Egyptian national bariatric registry data were found; one Egyptian single-surgeon series (I-BAR-105) and one Egyptian RCT (I-BAR-136) were identified.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check

Absolute risk and NNH; reproducibility of RR from rounded percentages – Risk difference 0.2% -> NNH ~500; RR 2.70 not exactly reproducible from 0.3%/0.1%. recalculated
Comparison of pooled Barrett estimates across sources – Range 0.3% (coded) to 18.8% (single centre); pooled meta-analyses 2.4-8%. recalculated

Certainty of the overall evidence (GRADE, simplified)

Main outcome

De novo Barrett's oesophagus attributable to sleeve gastrectomy

Starting level

low (observational studies)

Reasons for downgrading

inconsistency
indirectness (few controlled comparisons)
imprecision

Result

low

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked

IFSO: Position Statement on Upper GI Endoscopy Before and After MBS (I-BAR-114) (2025) · Original publication
Barrett incidence after MBS estimated at 2.4% (very heterogeneous, high likelihood of bias, little follow-up beyond 2 years); seven recommendations on endoscopy before/after MBS (recommendation text not in abstract, not used).
International expert consensus (Montpellier): GERD and LSG: First International Consensus Conference (I-BAR-113) (2020) · Original publication
GERD is probably the main drawback of LSG; endoscopy before (92%) and after (78%) surgery; higher-grade oesophagitis and Barrett are contraindications to LSG; RYGB recommended for uncontrolled GERD after sleeve.

Search strategy

Documented literature searches for this review (search strings in the original database syntax).

Database	Date	Search	Looking for	Hits
Europe PMC	26 October 2026	`(TITLE:"Barrett" OR TITLE:"endoscopic surveillance" OR TITLE:"endoscopy") AND (TITLE:"sleeve" OR TITLE:"bariatric") AND (TITLE:"consensus" OR TITLE:"guideline" OR TITLE:"position statement" OR TITLE:"statement")`	guidelines	16
Europe PMC	26 October 2026	`(TITLE:"esophageal adenocarcinoma" OR TITLE:"oesophageal adenocarcinoma" OR TITLE:"esophageal cancer" OR TITLE:"oesophageal cancer" OR TITLE:"esophagogastric cancer") AND (TITLE:"sleeve gastrectomy" OR TITLE:"bariatric" OR TITLE:"obesity surgery")`	both directions	33
PubMed	26 October 2026	`(sleeve gastrectomy[ti]) AND (gastroesophageal reflux[tiab] OR GERD[tiab]) AND (de novo[tiab]) AND (systematic review[pt] OR meta-analysis[pt] OR randomized controlled trial[pt])`	supporting evidence	22
PubMed	26 October 2026	`(sleeve gastrectomy[ti]) AND (proton pump inhibitor*[tiab] OR PPI[tiab]) AND (long-term[tiab] OR 10-year[tiab] OR 10 years[tiab]) AND (reflux[tiab])`	supporting evidence	37

Open questions

Long-term Barrett and cancer incidence after sleeve vs matched non-operated people with endoscopic surveillance in both groups.

How deeply was this checked?

11 linked studies: 0 checked in full text (0 of them with a structured risk-of-bias assessment), 11 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict

25 October 2026 · Phase 1 · Initial assessment: Potentially true (low)
26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Potentially true (low)
Unchanged (“Potentially true”, low). New data add both a non-surgical comparison suggesting a relative increase (I-BAR-115) and randomised/society data showing small or similar absolute rates (I-BAR-116, I-BAR-114).
New sources: I-BAR-109 I-BAR-115 I-BAR-116 I-BAR-110 I-BAR-114 I-BAR-117 I-BAR-145

In plain language

The archive says sleeve gastrectomy leaves the gullet exposed to Barrett's oesophagus. Barrett's changes are indeed found in some patients years after sleeve (about 6 in 100 in a pooled analysis). But the Finnish randomized trial quoted by the archive found the same rate (4%) after gastric bypass. So the trial does not show that sleeve specifically causes more Barrett's than bypass.

Studies on this claim

Studies supporting the claim (5)

Austrian follow-up 10+ years after sleeve

Felsenreich DM et al.. Obes Surg 2017 · PMID 28593484 · DOI 10.1007/s11695-017-2748-9

Case series / case reportcited by the Tayebat archiveabstract checked

Many patients had reflux and 15% had Barrett's changes, but the study was very small.

Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Long-term reflux
How was the study done?
Case series
How many people, animals or samples were studied?
43
What was actually found?
High BE rate
How large was the observed effect?
15%
What do the results mean in everyday life?
Signal of concern
What are the study's limitations?
Small, early technique
What does it say about Elawady's specific claim?
Partly supports
Do the results apply to Germany and Europe?
European
What can explicitly not be concluded from this study?
True incidence
Scientific details →
Endoscopy 5+ years after sleeve

Sebastianelli L et al.. Obes Surg 2019 · PMID 30666544 · DOI 10.1007/s11695-019-03704-y

Cross-sectional studycited by the Tayebat archiveabstract checked

About 1 in 5 had Barrett's changes; reflux symptoms rose from 22% to 76%.

Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Prevalence
How was the study done?
Cross-sectional
How many people, animals or samples were studied?
90
What was actually found?
High BE and GERD
How large was the observed effect?
BE 18.8%
What do the results mean in everyday life?
Reflux is frequent after sleeve
What are the study's limitations?
Small, no control
What does it say about Elawady's specific claim?
Supports reflux claim
Do the results apply to Germany and Europe?
European
What can explicitly not be concluded from this study?
Exact risk
Scientific details →
Meta-analysis: Barrett's after sleeve

Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041

Meta-analysisindependent cross-checkabstract checked★ key study

About 5.6% developed new Barrett's esophagus; reflux and acid-medication use were about 3 times more frequent after sleeve.

Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
BE after SG
How was the study done?
Meta-analysis
How many people, animals or samples were studied?
2046
What was actually found?
BE 5.6%; GERD x3
How large was the observed effect?
RR GERD 3.32
What do the results mean in everyday life?
Reflux is a major downside of sleeve
What are the study's limitations?
Heterogeneous observational
What does it say about Elawady's specific claim?
Supports reflux/BE claim, not 'inevitable'
Do the results apply to Germany and Europe?
Applicable
What can explicitly not be concluded from this study?
Cancer risk
Scientific details →
Meta-analysis: reflux after sleeve

Yeung et al.. Ann Surg 2020 · PMID 30921053 · DOI 10.1097/SLA.0000000000003275

Meta-analysisindependent cross-checkabstract checked★ key study

About 23 in 100 developed new reflux after sleeve, 28 in 100 had oesophagitis at long-term endoscopy, and 4 in 100 needed a second operation for reflux.

Barrett 8% pooled (likely overestimated).

Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Estimate reflux after sleeve
How was the study done?
Meta-analysis
How many people, animals or samples were studied?
10,718 patients
What was actually found?
De novo reflux 23%; oesophagitis 28%; Barrett 8%
How large was the observed effect?
Proportions
What do the results mean in everyday life?
Reflux is a frequent downside, not universal
What are the study's limitations?
Heterogeneous, uncontrolled
What does it say about Elawady's specific claim?
Supports "increases reflux"; contradicts "inevitable"
Do the results apply to Germany and Europe?
Applicable
What can explicitly not be concluded from this study?
Cancer risk
Scientific details →
Sleeve vs a weight-loss drug: Barrett changes

Butt et al.. Ann Gastroenterol 2026 · PMID 42164611 · DOI 10.20524/aog.2026.1058

Cohort studyindependent cross-checkabstract checked

Barrett changes were diagnosed in 0.3% after sleeve vs 0.1% with liraglutide; cancer did not differ.

BE RR 2.70 vs liraglutide, absolute 0.3% vs 0.1%.

Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Compare BE after SG vs liraglutide
How was the study done?
Matched EHR cohort
How many people, animals or samples were studied?
20,096
What was actually found?
BE 0.3% vs 0.1%
How large was the observed effect?
RR 2.70
What do the results mean in everyday life?
Small absolute increase
What are the study's limitations?
Detection bias
What does it say about Elawady's specific claim?
Supports a modest relative increase
Do the results apply to Germany and Europe?
US data
What can explicitly not be concluded from this study?
Cancer risk
Scientific details →

Studies contradicting or limiting the claim (2)

Finnish trial: sleeve vs bypass after 10 years

Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229

Randomised controlled trialcited by the Tayebat archiveabstract checked★ key study

Esophagitis was found in 31% after sleeve vs 7% after bypass; Barrett's esophagus was 4% in both groups.

Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Compare sleeve vs bypass
How was the study done?
RCT with 10-year follow-up
How many people, animals or samples were studied?
240 patients
What was actually found?
More esophagitis after sleeve; Barrett's equal
How large was the observed effect?
31% vs 7%; BE 4% vs 4%
What do the results mean in everyday life?
Sleeve often causes reflux damage; bypass less so
What are the study's limitations?
Attrition; small
What does it say about Elawady's specific claim?
Supports reflux claim, not sleeve-specific Barrett's
Do the results apply to Germany and Europe?
Directly European
What can explicitly not be concluded from this study?
Cancer risk
Scientific details →
Norwegian trial: bypass vs sleeve in type 2 diabetes

Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6

Randomised controlled trialindependent cross-checkabstract checked★ key study

After 5 years, diabetes was in remission in 50% after bypass vs 20% after sleeve; acid reflux was more common after sleeve, but Barrett changes were similar.

Barrett prevalence similar after SG and RYGB.

Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Compare RYGB and SG in T2D
How was the study done?
Randomised trial
How many people, animals or samples were studied?
109
What was actually found?
Bypass better for remission and weight; sleeve more acid reflux
How large was the observed effect?
RD 29.5%
What do the results mean in everyday life?
Bypass helps diabetes more but is not a cure
What are the study's limitations?
Small, single centre
What does it say about Elawady's specific claim?
Supports bypass preference for diabetes/reflux; contradicts "complete cure"
Do the results apply to Germany and Europe?
Directly European
What can explicitly not be concluded from this study?
Long-term hard outcomes
Scientific details →

Studies with mixed or unclear results (4)

Meta-analysis: reflux 4+ years after sleeve

Hajibandeh et al.. Curr Obes Rep 2023 · PMID 37535236 · DOI 10.1007/s13679-023-00521-4

Meta-analysisindependent cross-checkabstract checked★ key study

About 1 in 4 developed new reflux and about 7 in 100 had Barrett changes; authors think the Barrett figure may be too high.

De novo BE 6.7%, likely overestimated per authors.

Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Long-term reflux complications
How was the study done?
Meta-analysis
How many people, animals or samples were studied?
7,904 patients
What was actually found?
GORD 24.8%, BE 6.7%
How large was the observed effect?
Proportions
What do the results mean in everyday life?
Most patients do not get new reflux
What are the study's limitations?
Reporting bias
What does it say about Elawady's specific claim?
Contradicts "inevitable"
Do the results apply to Germany and Europe?
Applicable
What can explicitly not be concluded from this study?
Cancer risk
Scientific details →
International society statement on endoscopy and Barrett

Brown et al.. Obes Surg 2025 · PMID 41108366 · DOI 10.1007/s11695-025-08206-8

Guideline / position statementindependent cross-checkabstract checked★ key study

Barrett changes were found in about 2.4 in 100 people after weight-loss surgery, but data were weak and short-term.

Barrett after MBS pooled 2.4% with very heterogeneous data.

Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Guide endoscopy around surgery
How was the study done?
Position statement with systematic review
How many people, animals or samples were studied?
not stated
What was actually found?
BE 2.4% after MBS
How large was the observed effect?
Proportion
What do the results mean in everyday life?
Barrett can occur; check with endoscopy when indicated
What are the study's limitations?
Weak data
What does it say about Elawady's specific claim?
Smaller risk than archive implies; not zero
Do the results apply to Germany and Europe?
International
What can explicitly not be concluded from this study?
Sleeve-specific long-term risk
Scientific details →
French national study: oesophageal cancer after sleeve vs bypass

Lazzati et al.. Surg Obes Relat Dis 2025 · PMID 39799019 · DOI 10.1016/j.soard.2024.12.002

Cohort studyindependent cross-checkabstract checked★ key study

Oesophageal cancer was rare after both operations (about 4 per 100,000 per year after sleeve) and not significantly different.

Barrett-to-cancer concern not confirmed but not excluded.

Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Compare cancer risk SG vs GB
How was the study done?
National cohort
How many people, animals or samples were studied?
370,271
What was actually found?
No significant difference
How large was the observed effect?
HR 1.60 (0.90-2.5)
What do the results mean in everyday life?
Cancer of the gullet after sleeve is rare
What are the study's limitations?
Coding; borderline result
What does it say about Elawady's specific claim?
Contradicts "cancer comes decades earlier"; leaves small uncertainty
Do the results apply to Germany and Europe?
Directly European
What can explicitly not be concluded from this study?
Risk vs no surgery
Scientific details →
Trial follow-up: Barrett changes 7 years after sleeve or bypass

Lee et al.. ANZ J Surg 2025 · PMID 39829211 · DOI 10.1111/ans.19369

Randomised controlled trialindependent cross-checkabstract checked

Barrett changes were found in 8 of 26 examined sleeve patients and 3 of 22 bypass patients; the difference was not statistically certain.

Barrett 30.8% after LSG vs 13.6% after RYGB (NS; selected subgroup).

Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
BE after LSG vs LRYGB
How was the study done?
RCT follow-up
How many people, animals or samples were studied?
48
What was actually found?
30.8% vs 13.6%
How large was the observed effect?
P=0.19
What do the results mean in everyday life?
Endoscopy checks may be useful
What are the study's limitations?
Small, selected
What does it say about Elawady's specific claim?
Partly supports Barrett concern
Do the results apply to Germany and Europe?
Applicable
What can explicitly not be concluded from this study?
Cancer risk
Scientific details →

Regional context

Germany / EU

Egypt

What applies in my country?

General scientific assessment

Potentially true Barrett's is documented after sleeve, but the archive's key trial shows no sleeve-specific excess.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

Reflux, Sleeve Dilation, and Barrett's Esophagus after Laparoscopic Sleeve Gastrectomy: Long-Term Follow-Up.. Felsenreich DM et al.. Obes Surg 2017 · PMID 28593484 · DOI 10.1007/s11695-017-2748-9
Systematic Endoscopy 5 Years After Sleeve Gastrectomy Results in a High Rate of Barrett's Esophagus: Results of a Multicenter Study.. Sebastianelli L et al.. Obes Surg 2019 · PMID 30666544 · DOI 10.1007/s11695-019-03704-y
Risk of De Novo Barrett's Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up.. Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041
Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux?: A Systematic Review and Meta-analysis.. Yeung et al.. Ann Surg 2020 · PMID 30921053 · DOI 10.1097/SLA.0000000000003275
Incidence of Barrett's esophagus and esophageal cancer following sleeve gastrectomy versus liraglutide therapy.. Butt et al.. Ann Gastroenterol 2026 · PMID 42164611 · DOI 10.20524/aog.2026.1058
Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.. Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.. Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6
Meta-analysis of Long-term De Novo Acid Reflux-Related Outcomes Following Sleeve Gastrectomy: Evidence Against the Need for Routine Postoperative Endoscopic Surveillance.. Hajibandeh et al.. Curr Obes Rep 2023 · PMID 37535236 · DOI 10.1007/s13679-023-00521-4
International Federation for Surgery for Obesity and Metabolic Disorders Position Statement on the role of Upper Gastrointestinal Endoscopy Before and After Metabolic Bariatric Surgery.. Brown et al.. Obes Surg 2025 · PMID 41108366 · DOI 10.1007/s11695-025-08206-8
Risk assessment for esophageal cancer after bariatric surgery: a comparative cohort study between sleeve gastrectomy and gastric bypass.. Lazzati et al.. Surg Obes Relat Dis 2025 · PMID 39799019 · DOI 10.1016/j.soard.2024.12.002
Long-term effect of Roux-en-Y gastric bypass versus sleeve gastrectomy on reflux and Barrett's oesophagus: a randomized controlled trial.. Lee et al.. ANZ J Surg 2025 · PMID 39829211 · DOI 10.1111/ans.19369

← Back to overview

Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

Original statement

Translation

Origin

Scientific assessment

1. What was claimed?

2. What is demonstrably correct?

3. What is wrong or exaggerated?

4. What remains unclear?

5. Which studies support it?

6. Which studies contradict it?

7. What applies to Germany and Europe?

8. What is known about Egypt?

9. What practical conclusion is appropriate?

Assessment details

Scientific evidence in detail

What speaks for the claim?

Meta-analysis: Barrett's after sleeve

Sleeve vs a weight-loss drug: Barrett changes

What speaks against the claim?

Finnish trial: sleeve vs bypass after 10 years

Norwegian trial: bypass vs sleeve in type 2 diabetes

International society statement on endoscopy and Barrett

What does the overall evidence say?

Which position is better supported?

Why some studies weigh more

Remaining uncertainty

Justified conclusion

Open questions

How deeply was this checked?

In plain language

Studies on this claim

Studies supporting the claim (5)

Austrian follow-up 10+ years after sleeve

Endoscopy 5+ years after sleeve

Meta-analysis: Barrett's after sleeve

Meta-analysis: reflux after sleeve

Sleeve vs a weight-loss drug: Barrett changes

Studies contradicting or limiting the claim (2)

Finnish trial: sleeve vs bypass after 10 years

Norwegian trial: bypass vs sleeve in type 2 diabetes

Studies with mixed or unclear results (4)

Meta-analysis: reflux 4+ years after sleeve

International society statement on endoscopy and Barrett

French national study: oesophageal cancer after sleeve vs bypass

Trial follow-up: Barrett changes 7 years after sleeve or bypass

Regional context

Germany / EU

Egypt

What applies in my country?

General scientific assessment

References